Benzinga | Feb 25, 2021 11:43AM EST

Cowen & Co. Maintains Outperform on Guardant Health, Raises Price Target to $190

Cowen & Co. analyst Doug Schenkel maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $140 to $190.